1. Key Insights 2. Executive summary 3. Chronic Hand Eczema: Patient Overview at a Glance 3.1. Total Patient Share (%) Distribution of Chronic Hand Eczema in 2017 3.2. Total Patient Share (%) Distribution of Chronic Hand Eczema in 2030 4. Epidemiology and Market Methodology 5. Organizations 6. Chronic Hand Eczema: Disease Background and Overview 6.1. Introduction 6.2. Classification 6.3. Etiology 6.4. Symptoms 6.5. Risk Factors 6.6. Pathogenesis 6.7. Defining CHE Severity and Therapeutic Response 6.8. Diagnosis 6.8.1. Differential diagnosis 6.8.2. Guidelines for Diagnosis of hand eczema - European Society of Contact Dermatitis (ESCD) 6.9. Diagnostic Algorithm 7. Epidemiology and Patient Population 7.1. Key Findings 8. Total Prevalent Cases of Chronic Hand Eczema in 7MM 9. United States Epidemiology 9.1. Assumptions and Rationale 9.1.1. Total Prevalent Cases of Chronic Hand Eczema in the United States 9.1.2. Gender-Specific Cases of Chronic Hand Eczema in the United States 9.1.3. Diagnosed Cases of Chronic Hand Eczema in the United States 9.1.4. Severity Specific Cases of CHE in the United States 9.1.5. Subgroup-Specific Cases of CHE in the United States 9.1.6. Age-Specific Cases of CHE in the United States 10. EU5 Epidemiology 10.1. Germany Epidemiology 10.1.1. Assumptions and Rationale 10.1.2. Total Prevalent Cases of Chronic Hand Eczema in Germany 10.1.3. Gender-Specific Cases of Chronic Hand Eczema in Germany 10.1.4. Diagnosed Cases of Chronic Hand Eczema in Germany 10.1.5. Severity Specific Cases of CHE in Germany 10.1.6. Subgroup-Specific Cases of CHE in Germany 10.1.7. Age-Specific Prevalent Cases of CHE in Germany 10.2. France Epidemiology 10.2.1. Assumptions and rationale 10.2.2. Total Prevalent Cases of Chronic Hand Eczema in France 10.2.3. Gender-Specific Cases of Chronic Hand Eczema in France 10.2.4. Diagnosed Cases of Chronic Hand Eczema in France 10.2.5. Severity Specific Cases of CHE in France 10.2.6. Subgroup-Specific Cases of CHE in the United States 10.2.7. Age-Specific Cases of CHE in France 10.3. Italy Epidemiology 10.3.1. Assumptions and Rationale 10.3.2. Total Prevalent Cases of Chronic Hand Eczema in Italy 10.3.3. Gender-Specific Cases of Chronic Hand Eczema in Italy 10.3.4. Diagnosed Cases of Chronic Hand Eczema in Italy 10.3.5. Severity Specific Cases of CHE in Italy 10.3.6. Subgroup-Specific Cases of CHE in Italy 10.3.7. Age-Specific Cases of CHE in Italy 10.4. Spain Epidemiology 10.4.1. Assumptions and Rationale 10.4.2. Total Prevalent Cases of Chronic Hand Eczema in Spain 10.4.3. Gender-Specific Cases of Chronic Hand Eczema in Spain 10.4.4. Diagnosed Cases of Chronic Hand Eczema in Spain 10.4.5. Severity Specific Cases of CHE in Spain 10.4.6. Subgroup-Specific Cases of CHE in Spain 10.4.7. Age-Specific Cases of CHE in Spain 10.5. United Kingdom Epidemiology 10.5.1. Assumptions and Rationale 10.5.2. Total Prevalent Cases of Chronic Hand Eczema in the UK 10.5.3. Gender-Specific Cases of Chronic Hand Eczema in the UK 10.5.4. Diagnosed Cases of Chronic Hand Eczema in the UK 10.5.5. Severity Specific Cases of CHE in the UK 10.5.6. Subgroup-Specific Cases of CHE in the UK 10.5.7. Age-Specific Cases of CHE in the UK 11. Japan Epidemiology 11.1. Assumptions and Rationale 11.1.1. Total Prevalent Cases of Chronic Hand Eczema in Japan 11.1.2. Gender-Specific Cases of Chronic Hand Eczema in Japan 11.1.3. Diagnosed Cases of Chronic Hand Eczema in Japan 11.1.4. Severity Specific Cases of CHE in Japan 11.1.5. Subgroup-Specific Cases of CHE in Japan 11.1.6. Age-Specific Cases of CHE in Japan 12. KOL Views 13. Appendix 14. Report Methodology 15. DelveInsight Capabilities 16. Disclaimer 17. About DelveInsight

Table 1 Classification of Hand Eczema Table 2 Definition of subtypes of hand eczema Table 3 Etiological classification of Hand Eczema Table 4 Morphological classification of Hand Eczema Table 5 Characteristics of the various sub diagnostic groups Table 6 Subgroups of hand eczema and definitions Table 7 Risk factors for the development of HE Table 8 Physician’s global assessment for chronic hand eczema Table 9 Modified total lesion-symptom score Table 10 Scoring of the patch test according to ICDRG recommendations Table 11 Diagnostic Evaluation of Hand Eczema Table 12 Signs and symptoms of superficially similar lesions of the hand eczema Table 13 Recommendations for the Classification and diagnosis of Hand Eczema Table 14 Total Prevalent Cases of Chronic Hand Eczema in the 7MM (2017–2030) Table 15 Total Prevalent Cases of Chronic Hand Eczema in the US (2017–2030) Table 16 Gender-Specific Cases of CHE in the US (2017–2030) Table 17 Diagnosed Cases of Chronic Hand Eczema in the US (2017–2030) Table 18 Severity Specific Cases of CHE in the US (2017–2030) Table 19 Subgroup Specific Cases of CHE in the US (2017–2030) Table 20 Age-Specific Cases of CHE in the US (2017–2030) Table 21 Total Prevalent Cases of Chronic Hand Eczema in Germany (2017–2030) Table 22 Gender-Specific Cases of CHE in Germany (2017–2030) Table 23 Diagnosed Cases of Chronic Hand Eczema in Germany (2017–2030) Table 24 Severity Specific Cases of CHE in Germany (2017–2030) Table 25 Subgroup Specific Cases of CHE in Germany (2017–2030) Table 26 Age-Specific Cases of CHE in Germany (2017–2030) Table 27 Total Prevalent Cases of Chronic Hand Eczema in France (2017–2030) Table 28 Gender-Specific Cases of CHE in France (2017–2030) Table 29 Diagnosed Cases of Chronic Hand Eczema in France (2017–2030) Table 30 Severity Specific Cases of CHE in France (2017–2030) Table 31 Subgroup Specific Cases of CHE in France (2017–2030) Table 32 Age-Specific Cases of CHE in France (2017–2030) Table 33 Total Prevalent Cases of Chronic Hand Eczema in Italy (2017–2030) Table 34 Gender-Specific Cases of CHE in Italy (2017–2030) Table 35 Diagnosed Cases of Chronic Hand Eczema in Italy (2017–2030) Table 36 Severity Specific Cases of CHE in Italy (2017–2030) Table 37 Subgroup Specific Cases of CHE in Italy (2017–2030) Table 38 Age-Specific Cases of CHE in Italy (2017–2030) Table 39 Total Prevalent Cases of Chronic Hand Eczema in Spain (2017–2030) Table 40 Gender-Specific Cases of CHE in Spain (2017–2030) Table 41 Diagnosed Cases of Chronic Hand Eczema in Spain (2017–2030) Table 42 Severity Specific Cases of CHE in Spain (2017–2030) Table 43 Subgroup Specific Cases of CHE in Spain (2017–2030) Table 44 Age-Specific Cases of CHE in Spain (2017–2030) Table 45 Total Prevalent Cases of Chronic Hand Eczema in the UK (2017–2030) Table 46 Gender-Specific Cases of CHE in the UK (2017–2030) Table 47 Diagnosed Cases of Chronic Hand Eczema in the UK (2017–2030) Table 48 Severity Specific Cases of CHE in the UK (2017–2030) Table 49 Subgroup Specific Cases of CHE in the UK (2017–2030) Table 50 Age-Specific Cases of CHE in the UK (2017–2030) Table 51 Total Prevalent Cases of Chronic Hand Eczema in Japan (2017–2030) Table 52 Gender-Specific Cases of CHE in Japan (2017–2030) Table 53 Diagnosed Cases of Chronic Hand Eczema in Japan (2017–2030) Table 54 Severity Specific Cases of CHE in Japan (2017–2030) Table 55 Subgroup Specific Cases of CHE in Japan (2017–2030) Table 56 Age-Specific Cases of CHE in Japan (2017–2030) Figure 1 Epidemiology and Market Methodology Figure 2 Establish the diagnosis of acute hand dermatitis and chronic hand dermatitis (CHD) Figure 3 Skin immune system Figure 4 Photographic severity guide used in the physician’s global assessment scoring Figure 5 Flow chart for diagnosis of HE Figure 6 Diagnostic chronic hand eczema (CHE) algorithm Figure 7 Total Prevalent Cases of Chronic Hand Eczema in the 7MM (2017–2030) Figure 8 Total Prevalent cases of Chronic Hand Eczema in the US (2017–2030) Figure 9 Gender-Specific cases of CHE in the US (2017–2030) Figure 10 Diagnosed Cases of Chronic Hand Eczema in the US (2017–2030) Figure 11 Severity Specific Cases of CHE in the US (2017–2030) Figure 12 Subgroup Specific Cases of CHE in the US (2017–2030) Figure 13 Age-Specific Cases of CHE in the US (2017–2030) Figure 14 Total Prevalent cases of Chronic Hand Eczema in Germany (2017–2030) Figure 15 Gender-Specific cases of CHE in Germany (2017–2030) Figure 16 Diagnosed Cases of Chronic Hand Eczema in Germany (2017–2030) Figure 17 Severity Specific Cases of CHE in Germany (2017–2030) Figure 18 Subgroup Specific Cases of CHE in Germany (2017–2030) Figure 19 Age-Specific Cases of CHE in Germany (2017–2030) Figure 20 Total Prevalent cases of Chronic Hand Eczema in France (2017–2030) Figure 21 Gender-Specific cases of CHE in France (2017–2030) Figure 22 Diagnosed Cases of Chronic Hand Eczema in France (2017–2030) Figure 23 Severity Specific Cases of CHE in France (2017–2030) Figure 24 Subgroup Specific Cases of CHE in the US (2017–2030) Figure 25 Age-Specific Cases of CHE in France (2017–2030) Figure 26 Total Prevalent cases of Chronic Hand Eczema in Italy (2017–2030) Figure 27 Gender-Specific cases of CHE in Italy (2017–2030) Figure 28 Diagnosed Cases of Chronic Hand Eczema in Italy(2017–2030) Figure 29 Severity Specific Cases of CHE in Italy (2017–2030) Figure 30 Subgroup Specific Cases of CHE in Italy (2017–2030) Figure 31 Age-Specific Cases of CHE in Italy (2017–2030) Figure 32 Total Prevalent cases of Chronic Hand Eczema in Spain (2017–2030) Figure 33 Gender-Specific cases of CHE in Spain (2017–2030) Figure 34 Diagnosed Cases of Chronic Hand Eczema in Spain (2017–2030) Figure 35 Severity Specific Cases of CHE in Spain (2017–2030) Figure 36 Subgroup Specific Cases of CHE in Spain (2017–2030) Figure 37 Age-Specific Cases of CHE in Spain (2017–2030) Figure 38 Total Prevalent cases of Chronic Hand Eczema in the UK (2017–2030) Figure 39 Gender-Specific cases of CHE in the UK (2017–2030) Figure 40 Diagnosed Cases of Chronic Hand Eczema in the UK (2017–2030) Figure 41 Severity Specific Cases of CHE in the UK (2017–2030) Figure 42 Subgroup Specific Cases of CHE in the UK (2017–2030) Figure 43 Age-Specific Cases of CHE in the UK (2017–2030) Figure 44 Total Prevalent cases of Chronic Hand Eczema in Japan (2017–2030) Figure 45 Gender-Specific cases of CHE in Japan (2017–2030) Figure 46 Diagnosed Cases of Chronic Hand Eczema in Japan (2017–2030) Figure 47 Severity Specific Cases of CHE in Japan (2017–2030) Figure 48 Subgroup Specific Cases of CHE in Japan (2017–2030) Figure 49 Age-Specific Cases of CHE in Japan (2017–2030)